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Abstract We present the nucleotide and deduced amino acid 
sequences of a human cysteine string protein (csp) and a unique 
truncated csp variant that derives from the retention of an exonic 
sequence that introduces a premature, in-frame stop codon. Low 
stringency Southern analysis is compatible with the presence of a 
single human csp gene. Northern analysis reveals that human csp 
mRNA has both a more heterogeneous size distribution and a 
more widespread tissue distribution than previously reported for 
other csps. Exemplifying this is the fact that csp immuno- 
reactivity is detected in Triton X-114 extracts of human blood, 
an observation which may facilitate blood-based diagnostic 
assays of csp status in man. 
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I. Introduction 
Cysteine string proteins (csps) are extensively lipidated, cy- 
steine-rich proteins that are prominently localized at nerve 
endings of vertebrates and invertebrates ]14].  More recently, 
csps have also been detected in exocrine and endocrine secre- 
tory cells [4,5]. Csps are important  for the normal  release of 
neurotransmitter  at skeletal neuromuscular junct ions in Dro- 
sophila [6], and they have been implicated both in the regula- 
t ion of presynaptic alcium channels and in other phases of 
the secretory cascade [7-9]. Because of the neurological defi- 
cits and premature death of Drosophila csp mutants [6,9] and 
the possibility that defective csps may underlie disturbances of 
secretory and nervous system function in man, we cloned and 
sequenced human csp cDNAs and undertook a prel iminary 
characterization of human csps. Several interesting observa- 
tions emerged: (i) we obtained a human csp cDNA that pre- 
dicts a truncated form of csp that is shortened by about 30 
amino acid residues; (ii) low stringency Southern analysis im- 
plies that there is only a single human csp gene; (iii) relative 
to other species, Northern analysis reveals appreciably more 
heterogeneity in the mass distribution of human csp mRNAs  
as well as in the tissues where these mRNAs  are detected; (iv) 
finally, we provide immunoblot  evidence that csps are present 
in human blood, an observation that may have practical rel- 
evance for screening for structural disturbances of csps in 
man. 
2. Materials and methods 
2.1. Cloning and sequencing human csp cDNA 
A partial human csp cDNA clone was isolated by screening 6 x 10 s 
clones from a human brain lambda Zap II cDNA expression library 
(Stratagene) using afffinity-purified antibodies against a recombinant 
rat csp that had the cysteine string deleted (pilot experiments showed 
*Corresponding author. Fax: (1) (310) 206-5052. 
that these antibodies recognize a csp-like protein on immunoblots of 
membrane protein from post-mortem human brain). The nucleotide 
sequence of the 0.75 kb insert of this clone revealed that it was highly 
homologous to other csp cDNAs in that it encoded a J-domain and a 
cysteine string (e.g. see [2]). However, this initial clone lacked the 
initiation codon, so we used it as a probe to isolate additional cDNAs. 
Perhaps owing to secondary-structure complications, none of these 
additional clones (with inserts ranging from 1.2 to 3.0 kb) contained 
the 5' extremity of the csp open reading frame. In the end, we isolated 
two independent genomic sp clones (using a human genomic DNA 
library in lambda Dash II from Stratagene) with approximately 12 kb 
inserts. Restriction mapping and nucleotide sequencing of portions of 
this genomic DNA yielded the missing csp open reading frame and 
also gave insight into the origin of the truncated form of csp eDNA 
presented in Section 3. The nucleotide sequence was obtained for both 
DNA strands using a combination of subcloning and sequence-speci- 
fic primers. 
2.2. Southern analysis of human genomic DNA 
Samples of 2 Ixg of human genomic DNA (Promega) were cut with 
restriction endonucleases and prepared for Southern analysis exactly 
as described in [10]. Prehybridization was at 42°C in a solution of 25% 
formamide, 5x SSPE (1 x SSPE = 0.15 M NaC1, 10 mM NaH2PO4, 1 
mM EDTA), 5 X Denhardt's solution (1 × Denhardt's solution is: 1% 
Ficoll, 1% polyvinylpyrrolidine, 1% bovine serum albumin), 0.5% 
SDS, and 0.1 mg ml -~ of denatured salmon sperm DNA. After 4 h 
the prehybridization solution was replaced with hybridization solution 
that was supplemented with dextran sulfate (final concentration: 10%, 
w:v) and 32p-labeled probe obtained using random-prime labeling of 
a 1.8 kb, gel-purified, human csp cDNA (that lacks about 30 nucleo- 
tides of the 5' open reading frame). Hybridization was for 20 h at 
42°C after which the filter was washed in a flow apparatus (Millipore) 
with a final low stringency wash using 0.1 x SSPE, 0.1% SDS at 50°C. 
Bands were detected by autoradiography. 
2.3. Northern analysis 
We purchased a nitrocellulose filter from Clontech that has mRNA 
from several human tissues. Prehybridization and hybridization con- 
ditions were identical to those described for Southern analysis except 
that high stringency condition of hybridization (with 50% formamide) 
and wash (at 67°C rather than 50°C) were used, and the probe was the 
original 0.75 kb human csp cDNA fragment. 
2.4. Csps in human blood 
Fatty acylated csps partition effectively into the Triton X-114 phase 
during Triton X-114 phase partitioning experiments [11]. We exploited 
this fact to develop a procedure to extract csps from human blood 
samples: normally, 0.5 ml of fresh or frozen whole blood was diluted 
with 4.5 ml of 10 mM Tris, 1 mM EDTA (pH 7.4 with HCI) and 
Triton X-114 was added to 1% (v:v). Samples were incubated for 1-2 
h at 4°C with gentle agitation and insoluble material was removed by 
centrifugation for 5 min at 2000 X g. Samples were layered over a 1 ml 
cushion (of 6% sucrose in 0.1 M NaC1, 50 mM Tris, 1 mM EDTA 
with 0.05% Triton X-114 (pH 7.4 with HCI)) in a conical 15 ml 
centrifuge tube and incubated for 10 rain at 37°C. Condensed Triton 
X-114 was collected by centrifugation at 300-500 x g for 3 min. Pro- 
tein was recovered from the Triton X-114 bead using the procedure of 
Wessel and Flugge [12] and dissolved in SDS sample buffer with 5% 
SDS. Alternatively samples of the Triton X-114 bead were first treated 
with a final concentration f 1 M hydroxylamine (pH 7.2-7.5) or 1 M 
Tris (pH 7.4) with 50 mM dithiothreitol for 2 h at 22°C and then for 2 
h with 120 mM iodoacetamide in the dark before the extraction pro- 
cedure of [12]. Hydroxylamine treatment deacylates csps [3] and io- 
doacetamide alkylates the exposed thiol groups and reduces the for- 
mation of dimeric and multimeric sp complexes [11]. Subsequent 
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immunoblot analysis of csps was as described previously [8,11] using 
the same afffinity-purified anti-csp antibodies that were employed in 
the cloning experiments. To reduce background signal, the secondary 
goat anti-rabbit antibodies (conjugated to alkaline phosphatase) were 
preadsorbed against acetone powder of human blood as described in 
[13]. 
3. Results 
3.1. Human csp cDNAs and deduced amino acid sequences 
In the upper part of Fig. 1, we present he nucleotide and 
deduced amino acid sequence of human csp cDNA. This form 
of human csp is designated Hcspl. The predicted amino acid 
sequence of Hcspl differs only at position 112 (an F for a V) 
compared to rat csp ([2,5] and see corrected sequence in [14]), 
and at the nucleotide level there is 88% identity between rat 
and human csp cDNAs. Thus, these forms of rat and human 
csp are extremely highly conserved. 
Interestingly, one of the eight cDNA clones that we se- 
quenced had a 72 nucleotide insert that introduces an in-frame 
stop codon in the latter part of the csp open reading frame. 
This is indicated in the lower part of Fig. 1, where we show 
the nucleotide and predicted amino acid sequence of this 
shortened form of human csp (designated Hcsp2). The nucleo- 
tide sequence of Hcsp2 cDNA prior to and after the 72 nu- 
cleotide insert is identical to Hcspl (Fig. 1). However, the 
carboxy terminus of Hcsp2 is distinctly different from Hcspl 
(Fig. 1). It ends with two glycine residues and a histidine (Fig. 
1). This changes appreciably the net charge of Hcsp2 (it is less 
acidic than Hcspl), and it also removes a region rich in serine 
and threonine residues whose function is currently unknown. 
Based on sequence analysis of human csp genomic clones, 
Hcsp2 arises from the retention of a small 72 nucleotide xon 
that otherwise is removed from the mRNA encoding the 
Hcspl (results not shown). In spite of this truncation, both 
csp forms retain the characteristic cysteine string and a J-do- 
main [1,2,5,7], the latter motif presumably is involved in inter- 
actions with Hsp70 proteins [15]. 
3.2. Southern analysis 
Using as a probe a 1.8 kb human csp cDNA which begins 
approximately at nucleotide 30 in Fig. 1 (top), low stringency 
Southern analysis of human genomic DNA reveals a pattern 
(Fig. 2) that is consistent with the presence of a single human 
csp gene. For instance, a single band between 4 kb and 5 kb is 
detected in genomic DNA digested either with BamHI, KpnI 
or HindlII. Concomitantly, SacI is known to have single re- 
cognition site in the 1.8 kb human csp cDNA probe, and it 
produces the expected pair of bands. HinclI has multiple re- 
cognition sites in the csp gene and produces ix distinct bands 
ranging from about 0.4 kb which is barely visible to 7 kb (Fig. 
2). Overall, these results and preliminary analysis of the Hcsp 
genomic clones reveal that the human csp gene spans in the 
order of 15-20 kb (Fig. 2). 
3.3. Northern analysis 
Northern analysis reveals multiple csp mRNA species under 
high stringency conditions (Fig. 3). Except in kidney where 
only three bands were evident, all other tissues revealed at 
least four candidate csp mRNA species of about 1.3 kb, 3.5 
kb, 5 kb and 6 kb (Fig. 3). In addition, there was a fifth weak 
band in human muscle at about 1.8 kb. Interestingly, there is 
appreciable variation among the different issues in the rela- 
Human Csp primary sequence 
-60 tggtacttcatc~ctt~ctttctttt~ttttttct~tagaataagcctaa-i  
+i +60 
1 M A D Q R Q R S L S T S G E S L Y H V L  20 
+61 TGACA~ ' +~0 
21 G L D K N A T S D D I K K S Y R K L A L  40 
+121 AAATA ~ +180 
41 K Y H P D K N P D N P E A A D K F K E I  60 
+ 1 8 1 ~  +240 
61 N N A H A I L T D A T K R N I Y D K Y G  80 
+241 ~ + 3 0 0  
Sl S L G L Y V A E Q F G E E N V N T Y F V I 0 0  
+301 +360 
1 0 1 L S S W W A K A L F V F C G L L T C C Y I 2 0  
+ 3 6 1 ~ + ~ 0  
1 2 1 C C C C L C C C F N C C C G K C K P K A I 4 0  
+421 +480 
1 4 1 P E G E E T E F Y V S P E D L E A Q L Q I 6 0  
+481 ~ ~ + 5 4 0  
1 6 1 S D E R E A T D T P I V l Q P A S A T E I 8 0  
+541 ~ +597 
1 8 1 T T Q L T A D S H P S Y H T D G F N S t o p  
Htman CSP2 splice variant 
+475 +493 
ca~ctgtgccgcgagtg~t tgtggtgg 
L Q S D E R G G H Stop 
+494 +513 
cagc tgggactgtt4~aggtgtgaacgtggaccctga ~C 
Fig. 1. The nucleotide and deduced amino acid sequences of Hcspl 
and Hcsp2. (Top) The nucleotide and predicted amino acid se- 
quence of Hcspl using the single letter convention. (Bottom) Hcsp2 
has the same nucleotide sequence as Hcspl except for a 72 nucleo- 
tide insert shown here. This insert introduces two in-frame stop co- 
dons (in bold). The first stop codon predicts a truncated csp variant 
that is 167 amino acids rather than the 198 residues of Hcspl. 
tive intensity of the various putative csp mRNAs. For in- 
stance, the 1.3 kb species is most prominent in liver while 
the higher mass mRNAs are less abundant. The converse is 
true of csp mRNA in the brain and pancreas (Fig. 3). 
3.4. Immunoreactive csp in human blood 
In pilot experiments, we confirmed that our antibodies 
against recombinant rat csp recognized csp on immunoblots 
of human brain membranes (data not shown). Given the high 
homology between rat and human csps, this antibody cross- 
reactivity is not surprising. Thus, with the Northern data im- 
plying a widespread tissue distribution of csps, we were inter- 
ested in assessing whether csps might also be detected in hu- 
man blood. As indicated in Fig. 4 (lane A), a candidate csp 
immunoreactive band is detected at about 35 kDa. Evidence 
that this immunoreactive protein is csp comes from the find- 
ing that this species displays a 7 kDa downward shift in ap- 
parent mass after treatment with the deacylating agent, hy- 
droxylamine (Fig. 4, lane B). Treatment of the Triton X-114 
extract of human blood with 1 M Tris (pH 7.4) instead of 
hydroxylamine does not produce any apparent mass shift 
(Fig. 4, lane C) which is compatible with the effect of hy- 
droxylamine being due to deacylation of csp. Similar shifts 
in csp mass are seen for deacylated fish and rat csps [2,3]. 
4. Discussion 
Human csp (Hcspl) is remarkably similar to rat csp with 
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only a single predicted change at the amino acid level. This 
result indicates that evolution of the csp gene is relatively 
slow, a fact that may reflect the critical importance of csps 
to neurosecretion, or to secretion in general. Indeed, a similar 
high degree of primary sequence conservation has been seen in 
another synaptic vesicle protein, synaptotagmin, which shows 
97% identity between rat and man [16]. However, we also 
obtained evidence for a second form of human csp based on 
cDNA sequence analysis. Precedents exist in Drosophila for 
csp splice variants [1,9], but it was only very recently that a 
vertebrate csp splice variant was reported [17]. Interestingly, it 
appears that the human csp splice variant derives from the 
same processing mechanism as the bovine form [17]. It will be 
important to determine whether this truncated form of human 
csp exhibits a differential cellular (or subcellular) distribution 
as has been documented for insect and bovine csp splice var- 
iants [9,17]. 
Southern analysis at low stringency suggests that there is a 
single human csp gene. This conclusion should remain provi- 
sional until a more systematic search is made for other genes 
encoding csp-like proteins. Again, this is exemplified by refer- 
ence to synaptotagmin. Li and colleagues [18] recently re- 
ported four new synaptotagmin isoforms that are distinct var- 
iants of the four previously identified forms of this protein. 
Nucleotide sequences imply that these synaptotagmin iso- 
forms derive from unique genes, so this situation establishes 
a strong precedent for genetic and primary sequence diversity 
among proteins associated with secretory organelles. On this 
basis, it is possible that additional genes encoding csp-like 
proteins will be found. 
An interesting conclusion that emerges from a comparison 
of the Southern and Northern data is that the multiple 
mRNAs detected on the Northern almost certainly derive 
from transcription of the single csp gene detected by Southern 
analysis. This is because the genomic Southern analysis was 
conducted at low stringency, whereas Northern analysis was 
at high stringency. Thus, any mRNAs that were not tran- 
scribed from the csp gene revealed in Fig. 2 should not have 
been detected on the Northern. This implies then that the 3-5 
csp mRNA species een in different issues are probably due 
either to multiple transcription i itiation sites or to differential 
mRNA processing. Presumptive vidence for at least one csp 
BamH! Kpnl HindIll Sa¢l Hinell kb 
!i i ¸¸  ?!! 
!i !!~!~!?i~i!!i! i 
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Fig. 2. Human csp genomic Southern analysis. Human genomic 
DNA was digested with the indicated enzymes and probed at low 
stringency with a 1.8 kb csp cDNA probe. Bound probe was de- 
tected by autoradiography and approximate masses (in kb) are indi- 
cated. 
I 
- 9 .5  
- 7 .5  
- 4.4 
- 2 .4  
- 1 .4  
Fig. 3. A human tissue Northern blot was probed at high stringency 
using a 0.75 kb human csp cDNA probe. Bound probe was detected 
by autoradiography and mRNA masses are relative to standards 
(in kb). 
splice isoform is seen in the cDNA sequence for Hcsp2. The 
retention of a 72 nucleotide xon predicts a shortened form of 
csp with a modified C terminus relative to the original csp 
isoform. Thus, these two csp isoforms can account for two 
of the five csp mRNAs detected by Northern analysis, but 
further work will be needed to correlate specific csp isoforms 
with each mRNA. 
Besides the mass diversity of csp mRNAs, a second striking 
feature of the Northern analysis is the widespread tissue dis- 
tribution of csp mRNAs in man. This result was somewhat 
unexpected because in situ hybridization i Drosophila [1] and 
Northern analysis in Torpedo [19] had suggested that csp 
mRNAs were preferentially localized to nervous tissue. 
Although more recent work [4,5] has shown that csps are 
present in exocrine and endocrine secretory cells, the detection 
of csp mRNA in kidney, liver and placenta ran contrary to 
expectation. Interestingly, Chamberlain and Burgoyne [17] re- 
cently reported evidence from Northern analysis, RT-PCR, 
and immunoblots that csps are present in a variety of tissues, 
including, liver, spleen and kidney. These data were inter- 
preted as suggesting that csps play a more generalized role 
in secretion, rather than a specialized function in calcium 
channel modulation as previously proposed [8]. At one level, 
our results are compatible with this interpretation. Thus, we 
detect csp mRNA in a wide range of human tissues. However, 
what is needed is a clear indication of which cells in these 
tissues express csp. This cellular resolution is important for 
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Fig. 4. Immunoblot analysis of human blood samples. Protein re- 
covered from Triton X-114 extracts of human blood (equivalent to 
0.15 ml) was subjected to immunoblot analysis using anti-csp anti- 
bodies. Lane A: untreated control; lane B: deacylated sample (using 
hydroxylamine); lane C: sample treated with Tris as a control for 
hydroxylamine treatment. Note that the csp immunoreactive protein 
shows about a 7 kDa shift in apparent mass after deacylation i hy- 
droxylamine. 
the following reason. Most, if not all, vertebrate neurons ex- 
press csps [4]. Thus, in any given tissue, intrinsic neurons can 
contribute to the detectable csp immunoreactivity and csp 
mRNA. However, even in tissues with few or no intrinsic 
neurons (e.g. placenta), this issue is not resolved, because 
csps are present in blood. Therefore, further work will be 
necessary to validate the conclusion that csps participate 
more generically in secretory processes. 
It is reasonable to enquire what csps might be doing if their 
cellular distribution is as widespread as our results and those 
of Chamberlain and Burgoyne [17] suggest (with the above 
caveats). We previously advanced a model of csp function 
that is based on the unusual degree of fatty acylation of these 
proteins [20]. In recognition of the dramatic precedents for the 
similarity among many protein constituents of the secretory 
pathway (reviewed in [21-23]), we speculated that csps might 
participate in events that are critical for membrane fusion, not 
only in neurons, but in other cells, as well [20]. Thus, these 
recent results that argue for a broad cellular distribution of 
csps, may reflect this general role of csps in membrane traf- 
ficking. 
With the findings that csps are detectable in various non- 
neuronal secretory cells [4,5], we were interested in determin- 
ing whether csps could be detected in blood. In particular, 
because platelets and granulocytes exhibit regulated secretion, 
we expected that they might express csp-like proteins. Our 
results support this hypothesis. Using a Triton X-114 extrac- 
tion protocol, which excludes the vast excess of soluble hemo- 
globin in whole blood samples, we detected csp immunoreac- 
tivity in extracts from modestly sized samples of blood (0.1- 
0.5 ml). Again, additional work will be necessary to identify 
the cell(s) that harbor csps, but the presence of these proteins 
in blood offers the opportunity of using blood samples to 
assess structural perturbations of csps in man. 
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